Tilray Brands has bought the Canadian medical cannabis assets of HelloMD Corporation out of an insolvency sale. A court approved the deal on 29 June 2026. Tilray was the successful bidder in HelloMD’s formal sale process, and the terms were not disclosed.
HelloMD runs a telehealth platform that connects patients with practitioners authorised to certify medical cannabis use, then routes certified patients toward licensed producers. It has supported hundreds of thousands of patients in Canada through consultations, educational resources and personalised guidance.
For Tilray, the platform fills the last gap in its Canadian medical business. The company says the purchase completes a fully vertically integrated framework in its home market, linking cultivation, clinical expertise, practitioner support, product access and fulfilment.
Blair MacNeil, president of Tilray Canada, said the combined model creates “a more connected pathway for patients and healthcare practitioners in Canada.” He pointed to HelloMD’s practitioner network, Tilray’s licensed producer relationships and its national fulfilment capabilities.
HelloMD chief executive Larry Lisser said the company’s mission “from day one” was to make medical cannabis more accessible through technology, education and trusted healthcare experiences. “I believe Tilray has the expertise, infrastructure, and drive to expand the platform’s reach and impact, benefiting patients for years to come,” he said.
Where it fits
Tilray has built similar structures in more than 20 countries. They combine EU-GMP certified cultivation, pharmaceutical distribution through CC Pharma, medical cannabis clinics and digital pharmacy platforms. Its German network of clinics and digital pharmacies is one of the more developed examples in European cannabis.
Business of Cannabis noted that Canada’s medical channel has shrunk steadily since adult-use legalisation, as recreational sales absorbed demand and licensed producers faced pressure on prices and margins. Distressed operators with established networks, it said, are an increasingly attractive buy.
Tilray has been active on that front. It purchased the UK’s Lyphe Clinic this year, and the craft brewer BrewDog. Tilray Medical integrated Lyphe Group in April. Chief executive Irwin Simon told The Times that Tilray has put about £50m into BrewDog since buying it from administrators for £33m in March 2026.
Tilray also says it sees room in adjacent wellness categories such as sleep support and pain management, where over-the-counter products form a multi-billion-dollar market in which it is not meaningfully represented today. Subject to regulations, it plans to use HelloMD’s digital education tools to build awareness of regulated, plant-based medical cannabis among appropriate audiences.
Sources
- Tilray Acquires HelloMD in Court-Supervised Sale, Adding Direct-to-Patient Digital Infrastructure in Canada
- Tilray Brands Acquires HelloMD to Boost Medical Cannabis Access
